Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Rongtian Chen
- Telefonnummer: 16619724130
- E-mail: 376126340@qq.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age ≥50 years, any gender.
- The study eye must have active treatment-naïve macular neovascularization (MNV) secondary to AMD, confirmed by the investigator based on OCT images showing the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) involving the fovea.
- The study eye must have a best-corrected visual acuity (BCVA) measured using the 4-meter ETDRS chart of 24-78 ETDRS letters (approximately Snellen equivalent 20/320 - 20/32).
- Central subfield thickness (CST) ≥300 μm.
- The study eye has sufficiently clear ocular media and adequate pupillary dilation.
- Women of childbearing potential must use contraceptive measures during the study treatment period and for at least 3 months after the last dose.
- The patient and their legal representative are able to understand and sign the informed consent form, and are willing to comply with the follow-up and treatment plan specified in the study protocol.
- Patients with nAMD who have already been determined to receive the faricimab (4 loading doses + PRN) treatment regimen based on clinical need, for post-treatment observation.
- Only one eye will be selected as the study eye (if both eyes meet the criteria, the investigator will select the eye with worse visual acuity as the study eye).
Exclusion Criteria:
- Patients with ocular or periocular infection.
- Patients with active intraocular inflammation.
- Known hypersensitivity to faricimab or any of its excipients.
- Previous treatment with any other investigational therapy or any therapy that affects choroidal neovascularization (CNV) or macular neovascularization (MNV), or any therapy used for AMD.
- Presence of any ocular or systemic disease other than nAMD that may affect visual acuity assessment.
- Prior treatment in the study eye with anti-VEGF agents, corticosteroids, or laser therapy.
- Structural damage to the fovea in the study eye that is likely to prevent BCVA improvement even after resolution of macular edema (e.g., retinal pigment epithelial atrophy, subretinal fibrosis or scar, significant macular ischemia, or organized hard exudates).
- Presence of retinal pigment epithelial tear involving the macula in the study eye at screening.
- Uncontrolled glaucoma in the study eye.
- Refractive error in the study eye with spherical equivalent exceeding 6 diopters of myopia.
- Any cataract surgery or steroid treatment for cataract surgery complications in the study eye within 6 months prior to screening.
- Pregnant or breastfeeding women.
- Patients considered unsuitable for study enrollment by the investigator for other reasons.
- Inability to provide baseline clinical data (BCVA, visual contrast sensitivity, indocyanine green angiography (ICGA) images, optical coherence tomography angiography (OCTA) images, OCT images, color fundus photography (CFP) images) within 2 weeks (14 days) prior to the first faricimab treatment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Neovascular Age-related Macular Degeneration(nAMD) Group
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Choroidal Vascularity Index (CVI)
Tidsramme: Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
CVI represents the proportion of the total choroidal area occupied by blood vessels (luminal area).
|
Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
visual contrast sensitivity
Tidsramme: Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
Visual contrast sensitivity is the ability to detect differences in luminance (brightness) between an object and its background.
|
Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
|
Height of pigment epithelial detachment
Tidsramme: Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
The vertical distance between the detached retinal pigment epithelium (RPE) and the underlying Bruch's membrane.
|
Baseline, 4 weeks,8 weeks,12 weeks,16 weeks,24 weeks,48 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Chenjin Jin, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IIT2026006
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .